The report includes consensus-based recommendations, which consist of guidelines for the diagnosis and staging of LATE-neuropathological change—defined by stereotypical TDP-43 proteinopathy both with or without simultaneous hippocampal sclerosis pathology, in older adults.
Changes in MS diagnostic criteria and the availability of highly effective DMTs has deemed the risk for postpartum relapse nearly irrelevant for the majority of patients with MS.
The proprietary software utilizes sophisticated algorithms and 7T MRI data to predict the location of the subthalamic nuclei, a key target for deep brain stimulation for the treatment of Parkinson disease.
Researchers found that cognitively unimpaired patients with apneas had an average of 4.5% higher levels of tau in the entorhinal cortex than those who did not have apneas, after controlling for several other factors.
Conceptualizing risk among patients with traumatic brain injury requires clinicians to consider multiple factors including neuroanatomic and cognitive dysfunction, and psychosocial impairment.
Despite advances in neurology, a silent epidemic of older adults who sustain a TBI is growing. The authors provide tools and tips for a geriatric approach to treatment.
Neurology Times' inaugural Special Report explores TBI, providing key insights and practical strategies as well as focused approaches to clinical care.
The CAM options described here may help prevent trauma-related neurodegeneration over the long term.
The FDA announced that eszopiclone, zaleplon, and zolpidem will have a new boxed warning for rare, but serious injuries and deaths as a result of complex sleep behaviors caused by the medications.
While the overall link is only suggestive, new findings from a preliminary study have implied that there may be a link between sugar-sweetened beverage consumption and a higher disability status in MS.
The co-founder and CEO of Onera Health spoke about how Onera plans to revamp sleep diagnostics with its smart band-aid patches.
When combined with high-intensity statin therapy, treatment with alirocumab resulted in a 27% reduction in stroke risk, and 15% reduction in all-cause mortality.
Onera’s co-founder and chief medical officer, and the associate professor at John’s Hopkins University spoke about the plans for recently raised Series A funding and how a newly developed patch system could alter the diagnostics of sleep medicine.
Currently, there are no disease-modifying medications for Huntington disease and few interventions available to effectively alleviate symptoms, while the lack of indicators of pathobiological processes at the molecular level has limited the ability to prove efficacy and safety in clinical trials.
